Biovica International
Biovica awarded 3 MSEK contract — 4th from leading Tier-1 pharma company
Biovica, a leader in blood-based cancer monitoring, today announced its fourth’s work order with this Tier-1 pharmaceutical customer. This order is valued at approximately SEK 3 million. The project is expected to be fully executed during fall 2025.
This order extends the portfolio of ~25 MSEK in projects agreed with pharma companies active in developing new cancer treatments supported by DiviTum Tka. The project is scheduled for the latter part of 2025, and the revenues is planned to be recognized within this fiscal year.
The collaboration involves testing retrospective samples from a Phase III breast cancer study evaluating CDK4/6 inhibitors in combination with endocrine therapy. All samples will be analyzed in a single batch at Biovica’s CAP/CLIA-certified San Diego laboratory.
“We are excited to see the growing traction of our TKa biomarker among Tier-1 companies. While DiviTum TKa has been used retrospectively in other clinical trials, this marks the first time our biomarker is being applied retrospectively as part of our Pharma Collaborations business. This is yet another step to provide valuable insights for development of a companion diagnostic (CDx) for CDK4/6 inhibitors,” said Henrik Winther, Senior Vice President, Business Development at Biovica.
| Datum | 2025-07-24, kl 08:00 |
| Källa | MFN |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.